Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KNSA Kiniksa Pharmaceuticals Ltd.

交易中 01-12 12:03:26 EST

42.61

-0.06

-0.14%

最高42.82	最低41.65	成交量17.35万
今开42.70	昨收42.67	日振幅2.74%
总市值32.30亿	流通市值15.02亿	总股本7,580万
成交额737.28万	换手率0.49%	流通股本3,524万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KNSA","market":"US","secType":"STK","nameCN":"Kiniksa Pharmaceuticals Ltd.","latestPrice":42.61,"timestamp":1768237401541,"preClose":42.67,"halted":0,"volume":173476,"delay":0,"floatShares":35244400,"shares":75795759,"eps":0.466834,"marketStatus":"交易中","change":-0.06,"latestTime":"01-12 12:03:26 EST","open":42.7,"high":42.82,"low":41.65,"amount":7372820.727948001,"amplitude":0.02742,"askPrice":42.64,"askSize":100,"bidPrice":42.5,"bidSize":110,"shortable":3,"etf":0,"ttmEps":0.466834,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1768251600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1527134400000,"exchange":"NASDAQ","adjPreClose":42.67,"preHourTrading":{"tag":"盘前","latestPrice":42.69,"preClose":42.67,"latestTime":"09:28 EST","volume":146,"amount":6432.5045,"timestamp":1768228080041},"postHourTrading":{"tag":"盘后","latestPrice":42.67,"preClose":42.67,"latestTime":"17:35 EST","volume":6985,"amount":298052.39,"timestamp":1767998135134},"volumeRatio":0.686371,"impliedVol":0.4688,"impliedVolPercentile":0.5976},"requestUrl":"/m/hq/s/KNSA","defaultTab":"news","newsList":[{"id":"1157179476","title":"Kiniksa Pharmaceuticals：2026年下半年有望进行Kpl-387二期/三期心包炎复发试验的重点剂量部分","url":"https://stock-news.laohu8.com/highlight/detail?id=1157179476","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157179476?lang=zh_cn&edition=full","pubTime":"2025-10-28 19:35","pubTimestamp":1761651326,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals：2026年下半年有望进行Kpl-387二期/三期心包炎复发试验的重点剂量部分","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNSA","BK4505","BK4139"],"gpt_icon":0},{"id":"1195216708","title":"Kiniksa Pharmaceuticals International预期其当前运营计划将持续保持年度现金流正向","url":"https://stock-news.laohu8.com/highlight/detail?id=1195216708","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195216708?lang=zh_cn&edition=full","pubTime":"2025-10-28 19:33","pubTimestamp":1761651239,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals International预期其当前运营计划将持续保持年度现金流正向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNSA","BK4505","BK4139"],"gpt_icon":0},{"id":"1185079541","title":"Kiniksa Pharmaceuticals International Plc预计2025年Arcalyst净产品收入在6.7亿至6.75亿美元之间","url":"https://stock-news.laohu8.com/highlight/detail?id=1185079541","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185079541?lang=zh_cn&edition=full","pubTime":"2025-10-28 19:33","pubTimestamp":1761651198,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals International Plc预计2025年Arcalyst净产品收入将在6.7亿到6.75亿美元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNSA","BK4505","BK4139"],"gpt_icon":0},{"id":"1163026760","title":"Kiniksa Pharmaceuticals International Plc - Kpl-387 第二/第三阶段临床试验数据预计将于2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1163026760","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163026760?lang=zh_cn&edition=full","pubTime":"2025-10-17 20:05","pubTimestamp":1760702715,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals International Plc - Kpl-387 第二/第三阶段临床试验数据预计将于2026年下半年公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"1113612159","title":"Kiniksa Pharmaceuticals 宣布 Kpl-387 获得美国孤儿药资格，用于心包炎治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1113612159","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113612159?lang=zh_cn&edition=full","pubTime":"2025-10-17 20:04","pubTimestamp":1760702663,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals 宣布 Kpl-387 获得美国孤儿药资格，用于心包炎治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2556538826","title":"Kiniksa Pharmaceuticals, Ltd.2025财年第二财季实现净利润17.83百万美元，同比增加556.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556538826","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556538826?lang=zh_cn&edition=full","pubTime":"2025-08-03 00:01","pubTimestamp":1754150471,"startTime":"0","endTime":"0","summary":"8月3日，Kiniksa Pharmaceuticals, Ltd.公布财报，公告显示公司2025财年第二财季净利润为17.83百万美元，同比增加556.01%；其中营业收入为1.57亿美元，同比增加44.04%，每股基本收益为0.24美元。从资产负债表来看，Kiniksa Pharmaceuticals, Ltd.总负债1.66亿美元，其中短期债务2.52百万美元，资产负债比为3.99，流动比率为3.56。机构评级：截至2025年8月3日，当前有6家机构对Kiniksa Pharmaceuticals, Ltd.目标价做出预测，其中目标均价为45.17美元，其中最低目标价为38.00美元，最高目标价为54.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000133a6cf780f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250803000133a6cf780f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"gpt_icon":0},{"id":"2556848993","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556848993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556848993?lang=zh_cn&edition=full","pubTime":"2025-08-02 01:41","pubTimestamp":1754070104,"startTime":"0","endTime":"0","summary":"北京时间2025年08月02日01时41分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅上涨5.02%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为1.16%。其相关个股中，Evoke Pharma, Inc.、苏轩堂、美国联合医疗涨幅较大，Akanda Corp.、Incannex Healthcare Inc.、Evoke Pharma, Inc.较为活跃，换手率分别为345.58%、170.37%、7.67%，振幅较大的相关个股有Akanda Corp.、Evoke Pharma, Inc.、Incannex Healthcare Inc.，振幅分别为60.53%、20.09%、19.76%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080201414494c96dae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080201414494c96dae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA","BK4139","BK4505"],"gpt_icon":0},{"id":"2555052524","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 大幅拉升14.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555052524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555052524?lang=zh_cn&edition=full","pubTime":"2025-07-29 21:32","pubTimestamp":1753795953,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日21时32分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价急速拉升14.05%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为2.89%。其相关个股中，Durect Corporation、Kiniksa Pharmaceuticals, Ltd.、苏轩堂涨幅较大，Durect Corporation、Incannex Healthcare Inc.、大自然药业较为活跃，换手率分别为50.83%、13.97%、3.92%，振幅较大的相关个股有Scilex Holding Company、Incannex Healthcare Inc.、Tilray Brands, Inc.，振幅分别为13.34%、6.72%、4.97%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729213233a6c7f4cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729213233a6c7f4cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"2516299634","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 快速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516299634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516299634?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:36","pubTimestamp":1741012575,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时36分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价大幅上涨5.37%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.14%。其相关个股中，Sunshine Biopharma Inc C/Wts 、Scilex Holding Company、Intercure Ltd.涨幅较大，苏轩堂、Petros Pharmaceuticals, Inc.、大自然药业较为活跃，换手率分别为6.22%、2.94%、2.48%，振幅较大的相关个股有Redhill Biopharma Ltd、Organogenesis Holdings Inc.、Scilex Holding Company，振幅分别为7.50%、7.09%、6.36%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223616abe634c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223616abe634c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"2516552227","title":"Kiniksa Pharmaceuticals, Ltd.2024财年实现净利润-43.19百万美元，同比减少406.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516552227?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:00","pubTimestamp":1740844859,"startTime":"0","endTime":"0","summary":"3月2日，Kiniksa Pharmaceuticals, Ltd.公布财报，公告显示公司2024财年净利润为-43.19百万美元，同比减少406.75%；其中营业收入为4.23亿美元，同比增加56.67%，每股基本收益为-0.60美元。从资产负债表来看，Kiniksa Pharmaceuticals, Ltd.总负债1.42亿美元，其中短期债务1.99百万美元，资产负债比为4.10，流动比率为3.29。机构评级：截至2025年3月2日，当前有5家机构对Kiniksa Pharmaceuticals, Ltd.目标价做出预测，其中目标均价为34.20美元，其中最低目标价为30.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000115a259dc9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000115a259dc9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"gpt_icon":0},{"id":"1136511510","title":"Kiniksa Pharmaceuticals 2024年第四季度GAAP每股收益$(0.12)与$0.04预估不相符，销售额$1.2254亿未达到$1.2338亿预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1136511510","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136511510?lang=zh_cn&edition=full","pubTime":"2025-02-25 20:40","pubTimestamp":1740487253,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals报告季度每股亏损$，低于分析师一致预期的$0.04，下降了400%。去年同期每股收益为$0.35，同比下降了134.29%。公司报告季度销售额为$1.2254亿，未达到分析师一致预期的$1.2338亿，同比下降了0.68%。以上内容来自Benzinga Earnings专栏，原文如下：Kiniksa Pharmaceuticals  reported quarterly losses of $ per share which missed the analyst consensus estimate of $0.04 by 400 percent. This is a 134.29 percent decrease over earnings of $0.35 per share from the same period last year.  The company reported quarterly sales of $122.54 million which missed the analyst consensus estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kiniksa Pharmaceuticals 2024年第四季度GAAP每股收益$(0.12)与$0.04预估不相符，销售额$1.2254亿未达到$1.2338亿预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNSA"],"gpt_icon":0},{"id":"2510380357","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 急速跳水5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510380357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510380357?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:34","pubTimestamp":1739284460,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时34分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价快速下跌5.31%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为0.20%。其相关个股中，Evoke Pharma, Inc.、博美集团、Akanda Corp.涨幅较大，大自然药业、Quantum Biopharma Ltd.、Cbdmd, Inc.较为活跃，换手率分别为13.48%、2.63%、0.58%，振幅较大的相关个股有Incannex Healthcare Inc.、Organigram Holdings Inc.、Evoke Pharma, Inc.，振幅分别为6.28%、5.17%、5.17%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223420abcb06cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223420abcb06cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2509206868","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大涨5.40%报20.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509206868","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509206868?lang=zh_cn&edition=full","pubTime":"2025-02-07 00:26","pubTimestamp":1738859184,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日00时26分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价快速拉升5.40%。截至发稿，该股报20.69美元/股，成交量14.2226万股，换手率0.20%，振幅5.55%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为1.92%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002624a23be780&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002624a23be780&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2509723585","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘急速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509723585","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509723585?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:57","pubTimestamp":1738771075,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时57分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价快速拉升5.02%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为1.12%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205235755987b8bb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205235755987b8bb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA","BK4505","BK4139"],"gpt_icon":0},{"id":"2503589114","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌8.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503589114?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:31","pubTimestamp":1736778710,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时31分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价快速下挫8.43%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为0.42%。其相关个股中，Intra-Cellular Therapies Inc.、Citius Oncology, Inc.、Avadel Pharmaceuticals Plc涨幅较大，Intra-Cellular Therapies Inc.、Cbdmd, Inc.、大自然药业较为活跃，换手率分别为4.03%、3.33%、0.86%，振幅较大的相关个股有Sunshine Biopharma Inc.、Painreform Ltd.、Petros Pharmaceuticals, Inc.，振幅分别为99.66%、98.89%、7.71%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223150aba93080&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223150aba93080&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2491358806","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌5.02%报20.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491358806","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491358806?lang=zh_cn&edition=full","pubTime":"2024-12-13 01:53","pubTimestamp":1734026002,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日01时53分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅下挫5.02%。截至发稿，该股报20.18美元/股，成交量7.8649万股，换手率0.11%，振幅4.00%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为1.08%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213015322ab7304b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213015322ab7304b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","KNSA","FLGC","BK4505","BK4139","BK4183"],"gpt_icon":0},{"id":"2488975317","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌5.13%报20.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488975317","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488975317?lang=zh_cn&edition=full","pubTime":"2024-12-04 04:31","pubTimestamp":1733257905,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日04时31分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价急速跳水5.13%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.91%。其相关个股中，Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts 涨幅较大，Citius Oncology, Inc.、Painreform Ltd.、大自然药业较为活跃，换手率分别为140.57%、40.75%、39.33%，振幅较大的相关个股有Citius Oncology, Inc.、Medicus Pharma Ltd.、Sunshine Biopharma Inc C/Wts ，振幅分别为116.67%、45.51%、32.53%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204043145971b6d22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204043145971b6d22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MDCX","KNSA","BK4505","BK4139"],"gpt_icon":0},{"id":"2481930721","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 急速上涨5.04%报23.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481930721","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481930721?lang=zh_cn&edition=full","pubTime":"2024-11-07 03:37","pubTimestamp":1730921874,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日03时37分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅拉升5.04%。截至发稿，该股报23.14美元/股，成交量35.0814万股，换手率0.49%，振幅4.36%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为2.43%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107033754971a4dbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107033754971a4dbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"2480819875","title":"Kiniksa Pharmaceuticals, Ltd.2024财年第三财季实现净利润-12.69百万美元，同比增加8.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480819875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480819875?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:01","pubTimestamp":1730563288,"startTime":"0","endTime":"0","summary":"11月3日，Kiniksa Pharmaceuticals, Ltd.公布财报，公告显示公司2024财年第三财季净利润为-12.69百万美元，同比增加8.44%；其中营业收入为1.12亿美元，同比增加67.04%，每股基本收益为-0.18美元。从资产负债表来看，Kiniksa Pharmaceuticals, Ltd.总负债1.18亿美元，其中短期债务2.03百万美元，资产负债比为4.71，流动比率为0.04。机构评级：截至2024年11月3日，当前有6家机构对Kiniksa Pharmaceuticals, Ltd.目标价做出预测，其中目标均价为35.83美元，其中最低目标价为32.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000227ab98f592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000227ab98f592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"gpt_icon":0},{"id":"2479283855","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘急速下挫17.94%报22.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479283855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479283855?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:32","pubTimestamp":1730208750,"startTime":"0","endTime":"0","summary":"北京时间2024年10月29日21时32分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅下挫17.94%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体涨幅为0.14%。其相关个股中，Shuttle Pharmaceuticals Holdings, Inc.、Cyclo Therapeutics, Inc.、Im Cannabis Corp.涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Evoke Pharma, Inc.、Mira Pharmaceuticals, Inc.较为活跃，换手率分别为491.86%、13.90%、3.93%，振幅较大的相关个股有Shuttle Pharmaceuticals Holdings, Inc.、Kiniksa Pharmaceuticals, Ltd.、苏轩堂，振幅分别为10.35%、9.01%、4.76%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102921323095bd820f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102921323095bd820f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kiniksa.com","stockEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0524},{"period":"3month","weight":0.1262},{"period":"6month","weight":0.519},{"period":"1year","weight":1.102},{"period":"ytd","weight":0.0344}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kiniksa Pharmaceuticals International, plc于2015年7月21日在百慕大成立。该公司于2024年6月28日将公司注册地由百慕大变更为英国。该公司是一家生物制药公司，专注于发现、获取、开发和商业化治疗药物，为患有严重未满足医疗需求的使人衰弱的疾病的患者提供治疗药物。该公司的免疫调节组合ARCALYST、KPL-404和mavrilimumab基于强大的生物学原理或经过验证的机制，针对一系列未得到充分治疗的心血管和自身免疫疾病，并提供差异化的潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.00215},{"month":2,"riseRate":0.714286,"avgChangeRate":0.051474},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.059939},{"month":4,"riseRate":0.285714,"avgChangeRate":0.015075},{"month":5,"riseRate":0.714286,"avgChangeRate":0.005125},{"month":6,"riseRate":0.75,"avgChangeRate":0.052391},{"month":7,"riseRate":0.625,"avgChangeRate":0.052943},{"month":8,"riseRate":0.5,"avgChangeRate":0.032343},{"month":9,"riseRate":0.5,"avgChangeRate":0.011356},{"month":10,"riseRate":0.125,"avgChangeRate":-0.108256},{"month":11,"riseRate":0.875,"avgChangeRate":0.192866},{"month":12,"riseRate":0.5,"avgChangeRate":0.028542}],"exchange":"NASDAQ","name":"Kiniksa Pharmaceuticals Ltd.","nameEN":"Kiniksa Pharmaceuticals Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kiniksa Pharmaceuticals Ltd.(KNSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kiniksa Pharmaceuticals Ltd.,KNSA,Kiniksa Pharmaceuticals Ltd.股票,Kiniksa Pharmaceuticals Ltd.股票老虎,Kiniksa Pharmaceuticals Ltd.股票老虎国际,Kiniksa Pharmaceuticals Ltd.行情,Kiniksa Pharmaceuticals Ltd.股票行情,Kiniksa Pharmaceuticals Ltd.股价,Kiniksa Pharmaceuticals Ltd.股市,Kiniksa Pharmaceuticals Ltd.股票价格,Kiniksa Pharmaceuticals Ltd.股票交易,Kiniksa Pharmaceuticals Ltd.股票购买,Kiniksa Pharmaceuticals Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kiniksa Pharmaceuticals Ltd.(KNSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}